Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer

Seminars in Oncology

Volumn 29, Issue 1, 2002, Pages 87-94

  Bunn, Paul A ^a,b   Chan, Daniel C ^a,c   Earle, Keith ^a   Zhao, Tom L M ^a   Helfrich, Barbara ^a   Kelly, Karen ^a   Piazza, Gary ^a   Whitehead, Clark M ^a   Pamukcu, Rifat ^a   Thompson, William ^a   Alila, Hector ^a  

^a Cell Pathways Inc ^*

^b Cell Pathways Inc   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; PLATINUM DERIVATIVE; SULINDAC SULFONE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SURVIVAL TIME;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; PACLITAXEL; RATS; SULINDAC; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0036118264     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.31529     Document Type: Article

References (25)

1. Cancer statistics 2000
2. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)
3. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
4. Advanced non-small cell lung carcinoma: The emerging role of docetaxel
5. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens
6. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
7. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
8. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas
9. Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer
10. Inhibition of 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone-induced lung tumor formation by FGN-1 (sulindac sulfone)
11. Synergistic effects of new chemopreventative and conventional cytotoxic agents against human lung cancer cell lines
12. Non-small cell lung cancer cyclooxygenase activity and proliferation are inhibited by non-steroidal anti-inflammatory drugs
13. Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth
14. Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation and attenuated beta-catenin
15. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest and p53 induction
16. Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1
17. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines
18. Sulfone metabolite of sulindac inhibits mammary carcinogenesis
19. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis
20. A phase I study of exisulind in previously treated patients with lung cancer
21. A phase I and pharmacologic study of exisulind and docetaxel in patients with advanced cancer
22. Chemosensitivity testing of human lung cancer cell lines using the MTT assay
23. Analysis of combined drug effects: A new look at a very old problem
24. Nanomolar range docetaxel sensitizes MCF-7 cells to chemotherapy, induces apoptosis, induces G2M arrest and phosphorylates bcl-2
25. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy